This page shows the latest urothelial carcinoma news and features for those working in and with pharma, biotech and healthcare.
Roche’s drug is approved in a range of cancer types, including urothelial carcinoma, triple-negative cancer and hepatocellular carcinoma.
At the tail-end of last year, Seattle and Astellas scored US approval for Padcev (enfortumab vedotin) for the treatment of locally-advanced or metastatic urothelial carcinoma – the most common form ... The initial results from the phase 1b/2 EV-103
covers patients with early-stage high grade cancer cells – carcinoma-in-situ (CIS) – with or without papillary tumours. ... Keytruda has already been approved for first- and second-line treatment of urothelial carcinoma, another form of bladder
In May 2017, Bavencio (avelumab) claimed approval as a second-line treatment in patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease progressed during or following platinum-containing chemotherapy. ... Our unique
Merck’s blockbuster checkpoint inhibitor Keytruda (pembrolizumab) is also approved for first- and second-line treatment of urothelial carcinoma, the most common form of bladder cancer.
Padcev (enfortumab vedotin) is indicated for the treatment of locally-advanced or metastatic urothelial carcinoma – the most common form of bladder cancer – in adults who have previously been treated with chemotherapy ... Keytruda has already been
More from news
Approximately 3 fully matching, plus 33 partially matching documents found.
those living with urothelial carcinoma (UC), the most common type of bladder cancer.
Tecentriq (for the treatment of urothelial carcinoma, only approved in the US), and Venclexta (for the treatment of chronic lymphocytic leukaemia, approved in the EU and US).
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...